On
prescription drugs, lets fix what’s broken and improve what’s working
By Senate Finance Committee
Chairman Chuck Grassley of Iowa
Health
care is one of the top issues I hear about regularly from Iowans at my annual
99 county meetings. The affordability of prescription drugs, in particular, is
a major concern, and for good reason. The continual rise of prescription drug
costs has made it increasingly difficult for Iowans and all Americans to
receive the medications they depend on to survive and live a higher-quality
life.
A
survey released earlier this year by the West Health Institute found that more
than 80% of Iowa voters are worried about the cost of their prescription
medications. It also found that Iowans are not happy with the way Congress and
the federal government are handling the problem. I don’t blame them. The issue
of skyrocketing prescription drug prices has been kicked down the road by
members of Congress for far too long. That’s why as chairman of the Senate
Finance Committee, I’m introducing legislation that will directly address the
problem and provide relief to everyone struggling under outrageous drug prices.
The
bipartisan bill, which I’ve authored with Sen. Ron Wyden (D-Ore.), makes
important reforms in three specific areas: Medicare Parts B and D and Medicaid.
After months of working across the aisle to identify issues of consensus, we’re
proposing significant improvements that will not only help lower the cost of
prescription drugs, but also make substantive changes to the structure of these
programs to increase transparency and curb future abuses that lead to high
costs for consumers and taxpayers.
There
are more than 43 million people enrolled in Medicare Part D. Overall, they’re
happy with the choices available through the program. However, the
affordability of prescription drugs is a significant problem. Taxpayers are
also feeling the pinch of rising costs because of factors such as new drug
therapies and enrollment growth.
To
address these issues, this new bill changes the structure of Medicare Part D so
that insurance companies and pharmaceutical manufacturers would be responsible
for a larger share of the cost of medications. By requiring these entities to
have more skin in the game, they’re incentivized to keep costs lower for their
own interests, as well as those of consumers and taxpayers. The bill also
permanently eliminates gaps in coverage that lead to higher costs, and protects
patients by capping the amount that they pay out-of-pocket during the course of
the year.
The
bill also takes on the method of reimbursement of drugs given to patients in
doctors’ offices or hospital outpatient departments. The current method exposes
too many beneficiaries to high costs. By including more complete and accurate
reporting requirements, pricing calculations for prescriptions will improve and
patients will have to pay less out-of-pocket. Another important measure in the
bill is addressing incentives for doctors to prescribe the most expensive
drugs. By doing this, patients will have more opportunity to work with their
doctor to get the lowest-cost drug that works for them. Additionally, the
legislation addresses the year-after-year price hikes that put unnecessary
burdens on health care consumers. By putting a limit on what Medicare will pay,
pharmaceutical companies will be forced to reevaluate what they charge.
Finally,
this bill will make new and innovative medical treatments and therapies more
accessible to everyone, including Medicaid recipients. We live in a remarkable
time where gene therapies offer cures to diseases that were once deadly. Other
treatments are now available that bolster our immune cells to fight cancer.
These treatments shouldn’t be available only to those who can afford their
sticker price. However, the Medicaid program was not designed with these types
of medical innovations in mind. Provisions in this new legislation would
improve the Medicaid program to allow for greater access to these treatments,
as well as include good governance policies such as improved data collection
and transparency.
The truth is that no one piece of legislation will be able
to completely solve high prescription drug prices. It will take targeted
reforms and bipartisan cooperation. Congress can make real progress on
this issue by working across the aisle on areas of consensus to fix the
problems contributing to high drug costs and build on the pieces of the system
that are working. This bipartisan legislation does exactly that.
On prescription drugs, lets fix what’s broken and improve what’s working
On
prescription drugs, lets fix what’s broken and improve what’s working
By Senate Finance Committee
Chairman Chuck Grassley of Iowa
Health
care is one of the top issues I hear about regularly from Iowans at my annual
99 county meetings. The affordability of prescription drugs, in particular, is
a major concern, and for good reason. The continual rise of prescription drug
costs has made it increasingly difficult for Iowans and all Americans to
receive the medications they depend on to survive and live a higher-quality
life.
A
survey released earlier this year by the West Health Institute found that more
than 80% of Iowa voters are worried about the cost of their prescription
medications. It also found that Iowans are not happy with the way Congress and
the federal government are handling the problem. I don’t blame them. The issue
of skyrocketing prescription drug prices has been kicked down the road by
members of Congress for far too long. That’s why as chairman of the Senate
Finance Committee, I’m introducing legislation that will directly address the
problem and provide relief to everyone struggling under outrageous drug prices.
The
bipartisan bill, which I’ve authored with Sen. Ron Wyden (D-Ore.), makes
important reforms in three specific areas: Medicare Parts B and D and Medicaid.
After months of working across the aisle to identify issues of consensus, we’re
proposing significant improvements that will not only help lower the cost of
prescription drugs, but also make substantive changes to the structure of these
programs to increase transparency and curb future abuses that lead to high
costs for consumers and taxpayers.
There
are more than 43 million people enrolled in Medicare Part D. Overall, they’re
happy with the choices available through the program. However, the
affordability of prescription drugs is a significant problem. Taxpayers are
also feeling the pinch of rising costs because of factors such as new drug
therapies and enrollment growth.
To
address these issues, this new bill changes the structure of Medicare Part D so
that insurance companies and pharmaceutical manufacturers would be responsible
for a larger share of the cost of medications. By requiring these entities to
have more skin in the game, they’re incentivized to keep costs lower for their
own interests, as well as those of consumers and taxpayers. The bill also
permanently eliminates gaps in coverage that lead to higher costs, and protects
patients by capping the amount that they pay out-of-pocket during the course of
the year.
The
bill also takes on the method of reimbursement of drugs given to patients in
doctors’ offices or hospital outpatient departments. The current method exposes
too many beneficiaries to high costs. By including more complete and accurate
reporting requirements, pricing calculations for prescriptions will improve and
patients will have to pay less out-of-pocket. Another important measure in the
bill is addressing incentives for doctors to prescribe the most expensive
drugs. By doing this, patients will have more opportunity to work with their
doctor to get the lowest-cost drug that works for them. Additionally, the
legislation addresses the year-after-year price hikes that put unnecessary
burdens on health care consumers. By putting a limit on what Medicare will pay,
pharmaceutical companies will be forced to reevaluate what they charge.
Finally,
this bill will make new and innovative medical treatments and therapies more
accessible to everyone, including Medicaid recipients. We live in a remarkable
time where gene therapies offer cures to diseases that were once deadly. Other
treatments are now available that bolster our immune cells to fight cancer.
These treatments shouldn’t be available only to those who can afford their
sticker price. However, the Medicaid program was not designed with these types
of medical innovations in mind. Provisions in this new legislation would
improve the Medicaid program to allow for greater access to these treatments,
as well as include good governance policies such as improved data collection
and transparency.
The truth is that no one piece of legislation will be able
to completely solve high prescription drug prices. It will take targeted
reforms and bipartisan cooperation. Congress can make real progress on
this issue by working across the aisle on areas of consensus to fix the
problems contributing to high drug costs and build on the pieces of the system
that are working. This bipartisan legislation does exactly that.